
Conference Coverage
Latest Content

FDA Approves Giredestrant Plus Everolimus for ESR1-Mutated Breast Cancer

FDA Approves Generic Binimetinib for BRAF-Mutant Melanoma and NSCLC

Nurse Navigation and Long-Term Cancer Survivorship Insights

FDA Approves Pertuzumab Biosimilar Pebrilzo for HER2+ Breast Cancer

FDA Declines Ivonescimab Approval in EGFR+ NSCLC Over Survival Data

Shorts










Videos
Continuing Medical Education
All News

Cancer care teams are supporting more patients than ever, and oncology teams are navigating the clinical and operational realities that come with that growth.

A 5-decade SEER analysis found 5-year survival in young patients rose from 60% to 90%, yet non-Hispanic Black patients fared worst across cancers.

Nurses earn public trust through quiet acts of compassion, reassurance, and presence — a vital lifeline especially in oncology care.

Modeling projects anthracycline recipients may lose a median 9.4 life-years to age acceleration, a finding with survivorship care implications.

Oncology NPs and PAs are key to closing workforce gaps. Here’s how generalist, specialist, and hybrid APP models improve access and outcomes.

Perioperative durvalumab with enfortumab vedotin given only before cystectomy cut the risk of an EFS event by 49% in the phase 3 VOLGA trial.

With 10 years of oncology nursing experience, Lee Grabb highlights how nurse navigation, human connection, and compassion transform holistic cancer care.

Lisa Carter-Bawa, PhD, MPH, APRN, explains how blame keeps patients from lung cancer care and how nurses can counter that stigma in the community.

A study of 6 palliative care programs tied trust, proximity, and real-time communication with oncology teams to higher hospice use.

At the 10th Annual School of Nursing Oncology, faculty said nurses need fast, disease-specific updates to educate patients and manage novel therapies.

Experts detail evidence for exercise, acupuncture, and mind-body care during radiation, and the knowledge and referral gaps that limit uptake.

The PCR-based tissue assay can now identify patients with MSI-high solid tumors who may be candidates for pembrolizumab.

An 18-year analysis of a foundation program found trial-related travel, lodging, and caregiving costs varied by income, distance, and trial phase.

Coral Omene, MD, PhD, discusses the clinical impact of breast cancer disparities and how oncology nurses can support diverse trial recruitment.

Jessica Miles, MS, RN, CNS, explains how bench testing showed pumps and filters did not compromise stem cell infusion safety.































































